What Is ABT Fair Value?
Abbott Laboratories (ABT) fair value estimate using multiple valuation models, updated daily.
As of October 31, 2026, Abbott Laboratories (ABT) has a composite fair value estimate of $65.36 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $106.20, suggesting the stock is overvalued by 38.5%.
Data as of October 31, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$65.36
vs. current price of $106.20(-38.5%)
How Is ABT Fair Value Calculated?
Four independent models estimate what ABT is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ABT Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$64.78
-39.0%Overvalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$64.97
-38.8%Overvalued
Inputs used
ABT Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$60.56
-43.0%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$55.19
-48.0%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $106.20 is 39.0% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $5.25B | $4.90B |
| Year 2 | $5.64B | $4.91B |
| Year 3 | $6.06B | $4.92B |
| Year 4 | $6.50B | $4.93B |
| Year 5 | $6.98B | $4.95B |
| Year 6 | $7.50B | $4.96B |
| Year 7 | $8.05B | $4.97B |
| Year 8 | $8.64B | $4.98B |
| Year 9 | $9.28B | $4.99B |
| Year 10 | $9.96B | $5.00B |
| Terminal Value | $220.00B | $110.37B |
What Are ABT's Key Financial Metrics?
Earnings & Growth
Current Price
$106.20
EPS (TTM)
$2.69
Forward P/E
17.9
Profit Margin
9.7%
Cash & Balance Sheet
Free Cash Flow
0
EBITDA
12B
Book Value
$29.54
Total Debt
32.7B
What Do Analysts Say About ABT?
Low
$100.00
Average
$118.52
High
$130.00
Upside
+11.6%
ABT Fair Value FAQ
What is the fair value of ABT?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ABT's estimated fair value is $65.36. The stock is currently trading at $106.20, which makes it overvalued by our analysis.
How is ABT's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ABT overvalued or undervalued?
Based on our analysis, ABT is overvalued. The current price of $106.20 is 38.5% above our estimated fair value of $65.36.
What do Wall Street analysts say about ABT?
26 analysts cover Abbott Laboratories with a consensus rating of "Buy." The average price target is $118.52, ranging from $100.00 to $130.00. This implies 11.6% upside from the current price.